Home    中文  
 
  • Search
  • lucene Search
  • Citation
  • Fig/Tab
  • Adv Search
Just Accepted  |  Current Issue  |  Archive  |  Featured Articles  |  Most Read  |  Most Download  |  Most Cited

Chinese Journal of Clinical Laboratory Management(Electronic Edition) ›› 2020, Vol. 08 ›› Issue (01): 54-59. doi: 10.3877/cma.j.issn.2095-5820.2020.01.010

Special Issue:

• Experience Exchange • Previous Articles     Next Articles

Practical experience of large-scale detecting 2019-nCOV in third-party independent laboratories

Yong Liu1, Zhengyu Zeng2, Zhenjun Jiang2, Danping Liu2, Ran Tao3, Chanjun Ren4, Juan Du4, Miao Li4, Shuguang Xie3, Weimin Liu2, Genshi Li5, Huiyuan Li5, Yating Cheng1,()   

  1. 1. Guangzhou Kingmed Center for Clinical Laboratory, Guangzhou 510005, China; Research Certer for Clinical Virology of National Clinical Research Center for Respiratory Disease, Guangzhou 510005, China; Guangzhou Medical University, Guangzhou 510006, China
    2. Guangzhou Kingmed Center for Clinical Laboratory, Guangzhou 510005, China
    3. Guangzhou Kingmed Center for Clinical Laboratory, Guangzhou 510005, China; Guangzhou Medical University, Guangzhou 510006, China
    4. Wuhan Kingmed Center for Clinical Laboratory, Wuhan 430100, China
    5. Wuhan Kingmed Center for Clinical Laboratory, Wuhan 430100, China; Research Certer for Clinical Virology of National Clinical Research Center for Respiratory Disease, Wuhan 430100, China
  • Received:2020-02-20 Online:2020-02-28 Published:2020-02-28
  • Contact: Yating Cheng
  • About author:
    Corresponding author: Cheng Yating, Email:

Abstract:

A novel coronavirus pneumonia outbroke in Wuhan at the end of 2019. As an acute respiratory infectious disease, it has been included in class B infectious diseases under the infectious disease prevention act of the People's Republic of China and is managed according to class A infectious diseases. Based on the "Novel coronavirus pneumonia diagnosis and treatment formula", the detection of viral nucleic acid in respiratory tract specimen by RT-PCR is one of the confirmed plans of this disease. It is to be noted that a standardized and efficient novel coronavirus nucleic acid detection process is necessary to ensure the safety and reliability of laboratory personnel and to meet the requirements of epidemic prevention and control. KindMed Diagnostics undertakes large-scale testing tasks of 2019-nCOV and constantly optimizes the process under the advice of experts and colleagues. This paper presents here the relevant practical experience.

Key words: Novel coronavirus, Polymerase chain reaction, Protection

京ICP 备07035254号-20
Copyright © Chinese Journal of Clinical Laboratory Management(Electronic Edition), All Rights Reserved.
Tel: 020-81341720 Fax: 020-37103505 E-mail: clinlab@cma.org.cn
Powered by Beijing Magtech Co. Ltd